Douglas Lane & Associates LLC Acquires 52,032 Shares of GSK plc (NYSE:GSK)

Douglas Lane & Associates LLC raised its position in GSK plc (NYSE:GSKGet Rating) by 3.0% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 1,794,279 shares of the pharmaceutical company’s stock after buying an additional 52,032 shares during the period. Douglas Lane & Associates LLC owned about 0.07% of GSK worth $78,159,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Tyler Stone Wealth Management bought a new position in GSK in the 4th quarter valued at $26,000. Allegheny Financial Group LTD acquired a new position in shares of GSK in the 4th quarter valued at $27,000. Clearview Wealth Advisors LLC acquired a new position in shares of GSK in the 4th quarter valued at $27,000. Glassman Wealth Services lifted its stake in shares of GSK by 71.3% in the 4th quarter. Glassman Wealth Services now owns 627 shares of the pharmaceutical company’s stock valued at $28,000 after purchasing an additional 261 shares during the period. Finally, Paragon Capital Management Ltd acquired a new position in shares of GSK in the 4th quarter valued at $31,000. Hedge funds and other institutional investors own 32.76% of the company’s stock.

A number of research firms have recently weighed in on GSK. JPMorgan Chase & Co. increased their price target on GSK from GBX 1,740 ($21.07) to GBX 1,900 ($23.01) in a research note on Thursday, April 28th. Barclays increased their price target on GSK from GBX 1,775 ($21.49) to GBX 1,800 ($21.80) in a research note on Friday, April 29th. Finally, StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $1,850.00.

Shares of GSK stock opened at $43.30 on Wednesday. The company has a market capitalization of $110.06 billion, a PE ratio of 15.63, a PEG ratio of 1.96 and a beta of 0.61. GSK plc has a 12 month low of $37.80 and a 12 month high of $46.97. The company has a current ratio of 1.19, a quick ratio of 0.95 and a debt-to-equity ratio of 1.29. The stock’s fifty day simple moving average is $43.58 and its 200 day simple moving average is $43.81.

GSK (NYSE:GSKGet Rating) last issued its quarterly earnings data on Wednesday, April 27th. The pharmaceutical company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.77 by $0.11. The business had revenue of $13.12 billion for the quarter, compared to the consensus estimate of $11.97 billion. GSK had a return on equity of 28.13% and a net margin of 14.03%. Analysts predict that GSK plc will post 3.16 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Friday, July 1st. Investors of record on Friday, May 20th were paid a dividend of $0.3496 per share. This represents a $1.40 annualized dividend and a yield of 3.23%. The ex-dividend date of this dividend was Thursday, May 19th. GSK’s payout ratio is presently 48.38%.

GSK Company Profile (Get Rating)

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Stories

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.